Inflammation, aspirin, and the risk of cardiovascular disease
Rus, H.; Niculescu, F.I.
New England Journal of Medicine 337(6): 423; Author Reply 423-424
1997
ISSN/ISBN: 0028-4793 PMID: 9244848 Document Number: 482400
Document emailed within 1 workday
Related Documents
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25Mallonee, S.; Daniels, C.G.; Mold, J.W.; Cline, T.L. 2010: Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma Journal of the Oklahoma State Medical Association 103(7): 254-260
Miser, W.Fred. 2011: Appropriate aspirin use for primary prevention of cardiovascular disease American Family Physician 83(12): 1380-1386
Heald, A.H. 2007: Subclinical inflammation, C-reactive protein and cardiovascular risk Indian Journal of Medical Research 125(4): 502-504
Owens, D.K. 2017: Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF American Family Physician 95(4): 222-223
Nanda, N.; Bobby, Z.; Hamide, A. 2011: Inflammation and oxidative stress in hypothyroids: additive effects on cardiovascular risk Indian Journal of Physiology and Pharmacology 55(4): 351-356
José; A. Páramo; Orbe, J. 2002: Hemostasis, Inflammation and Cardiovascular Disease Clinical Laboratory 48(9-10): 463-410
De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
McKee, S.A.; Sane, D.C.; Deliargyris, E.N. 2002: Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance Thrombosis and Haemostasis 88(5): 711-715
Aghaeishahsavari, M.; Noroozianavval, M.; Veisi, P.; Parizad, R.; Samadikhah, J. 2006: Cardiovascular disease risk factors in patients with confirmed cardiovascular disease Saudi Medical Journal 27(9): 1358-1361
Hall, N.R.S. 2013: Diagnosing cardiovascular disease from the perspective of the brain and inflammation Alternative Therapies in Health and Medicine 19(Suppl 1): 8-9
De Caterina, R. 2001: The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice Italian Heart Journal. Supplement: Official Journal of the Italian Federation of Cardiology 2(6): 681-684
Gonzalez-Gay, M.A.; Llorca, J.; Garcia-Unzueta, M.T.; Gonzalez-Juanatey, C.; De Matias, J.M.; Martin, J.; Redelinghuys, M.; Woodiwiss, A.J.; Norton, G.R.; Dessein, P.H. 2008: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis Clinical and Experimental Rheumatology 26(4): 596-603
Sullivan, J.L. 1982: Iron, aspirin, and heart disease risk JAMA 247(6): 751
Lowe, G.; Rumley, A.; Norrie, J.; Ford, I.; Shepherd, J.; Cobbe, S.; Macfarlane, P.; Packard, C. 2000: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study Thrombosis and Haemostasis 84(4): 553-558
Lala, A.; Berger, J.S. 2011: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding Evidence-Based Medicine 16(3): 80-81
Elwood, P.C. 2001: Reducing the risk: heart disease, stroke and aspirin Journal of the Medical Association of Thailand 84(8): 1164-1174
Coady, S.A.; Sharrett, A.Richey.; Zheng, Z-Jie.; Evans, G.W.; Heiss, G. 2002: Vasectomy, inflammation, atherosclerosis and long-term followup for cardiovascular diseases: no associations in the atherosclerosis risk in communities study Journal of Urology 167(1): 204-207
Elliott, H.L. 1998: Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point? Journal of Cardiovascular Pharmacology 32(Suppl 3): S74-S77
Fellah, H.; Feki, M.; Feki, H.; Souissi, M.; Kaabachi, N.; Abdallah, T.B.; Massy, Z.A.; Maiz, H.B.; Lacour, B.; Mebazaa, A. 2004: Classical and "Non-classical" Cardiovascular Risk Factors in Tunisian Patients with End Stage Renal Disease: Prevalence and Association with Cardiovascular Events Clinical Laboratory 50(7-8): 447-453